FDA hastens development of Novartis' Kymriah in follicular l...

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene

Real-world data backs Kymriah’s safety profile, says Novarti...

Novartis' Kymriah okayed for funding in Scotland for lymphom...

Novartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness body recommended funding in an aggressive form of lymphoma

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novar

NICE approves Novartis' CAR-T therapy for diffuse large B-ce...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.